A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128

Abstract Background: An understanding of the relationships among allelic variability and clinical outcomes will be critical if HIV-infected patients are to benefit from the explosion in knowledge in human genomics. Human DNA banks must allow future analyses while addressing confidentiality, ethical, and regulatory issues. Method: A multidisciplinary group of clinical investigators, ethicists, data managers, regulatory specialists, and community representatives developed Adult AIDS Clinical Trials Group (AACTG) Protocol A5128. Participants in past or present AACTG clinical trials may contribute DNA. Extraction from whole blood is performed at a central laboratory, where participants' unique identifiers are replaced by randomly assigned identifiers prior to DNA storage. To identify genotype-phenotype relationships, genetic assay results can be temporarily linked to clinical trials data. Results: Institutional review boards in 21 states and Puerto Rico have approved Protocol A5128, and accrual is ongoing. Of the first 4,247 enrollees, 82% are male, 56% are white, 26% are African American, and 15% are Hispanic. Because participants may participate in multiple AACTG protocols, these represent 11,424 cases in 324 different AACTG studies and substudies, with at least 100 participants from 24 different studies. Studies exploring specific genotype-phenotype relationships are underway. Conclusion: The AACTG DNA bank will be an important resource for genomic discovery relevant to HIV therapy.

[1]  Alex J White,et al.  Mitochondrial toxicity and HIV therapy , 2001, Sexually transmitted infections.

[2]  M. Bondy,et al.  Ethical issues of genetic testing and their implications in epidemiologic studies. , 1997, Annals of epidemiology.

[3]  B. Knoppers,et al.  Bioethics for clinicians: 14. Ethics and genetics in medicine. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[4]  A. Roses.  SNPs—where's the beef? , 2002, The Pharmacogenomics Journal.

[5]  N. Holtzman,et al.  Ethical and legal issues in genetic epidemiology. , 1997, Epidemiologic reviews.

[6]  H. Greely,et al.  Genomics Research and Human Subjects , 1998, Science.

[7]  R. Kim,et al.  Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.

[8]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[9]  Harry Greenberg,et al.  Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study. , 2002, Controlled clinical trials.

[10]  E. Boerwinkle,et al.  Impact of the Human Genome Project on epidemiologic research. , 1997, Epidemiologic reviews.

[11]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[12]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[13]  L. Strong,et al.  Certificates of confidentiality: a valuable tool for protecting genetic data. , 1995, American journal of human genetics.

[14]  Marvin R Natowicz,et al.  Individual, family, and societal dimensions of genetic discrimination: A case study analysis , 1996, Science and engineering ethics.

[15]  M. Carrington,et al.  Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy , 2000, AIDS.

[16]  A. Telenti,et al.  Individualising HIV treatment—pharmacogenetics and immunogenetics , 2002, The Lancet.

[17]  C. Kozma,et al.  Genetic Discrimination: Perspectives of Consumers , 1996, Science.

[18]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[19]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[20]  M. Khoury,et al.  Genetic epidemiology and the future of disease prevention and public health. , 1997, Epidemiologic reviews.

[21]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[22]  Thomas A Trikalinos,et al.  Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.

[23]  M. Lederman,et al.  Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. , 1999, JAMA.

[24]  J. Leiden.  The genetics of dilated cardiomyopathy--emerging clues to the puzzle. , 1997, The New England journal of medicine.

[25]  K. K. Jain.  Biochips for Gene Spotting , 2001, Science.

[26]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[27]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[28]  K. Merikangas,et al.  Genetic epidemiology of psychiatric disorders. , 1997, Epidemiologic reviews.

[29]  P. Debré,et al.  CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. , 2000, AIDS.

[30]  J. Johnson,et al.  Pharmacogenomics: the inherited basis for interindividual differences in drug response. , 2001, Annual review of genomics and human genetics.

[31]  Rothstein Ma.  Genetic testing: employability, insurability, and health reform. , 1995 .

[32]  M R Natowicz,et al.  Discrimination as a consequence of genetic testing. , 1992, American journal of human genetics.

[33]  C. Leport,et al.  Ethical reflections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients. , 2002, Pharmacogenetics.

[34]  S. Spector,et al.  The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment. , 2000, The Journal of infectious diseases.

[35]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[36]  B. Trock,et al.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. , 1996, JAMA.

[37]  L M Kopelman,et al.  Informed consent for genetic research on stored tissue samples. , 1995, JAMA.

[38]  A. Syvänen.  Accessing genetic variation: genotyping single nucleotide polymorphisms , 2001, Nature Reviews Genetics.